Clinical Trial Update: Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age [Phase 3]

View source ↗

Summary

Open-label extension study of vortioxetine in children and adolescents with major depressive disorder was terminated after completion of the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder in Children and Adolescents

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Depressive Disorder, Major | Phase 3 | Status: TERMINATED | Results posted: 2022-12-28